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Abstract
Electrical properties of cells determine most of the cellular functions, particularly ones which
occur in the cell’s membrane. Manipulation of these electrical properties may provide a powerful
electrotherapy option for the treatment of cancer as cancerous cells have been shown to be more
electronegative than normal proliferating cells. Previously, we used an electrical impedance sensing
system (EIS) to explore the responses of cancerous SKOV3 cells and normal HUVEC cells to low
intensity (<2 V/cm) AC electric fields, determining that the optimal frequency for SKOV3 proliferation arrest was 200 kHz, without harming the non-cancerous HUVECs. In this study, to determine if these effects are cell type dependant, human breast adenocarcinoma cells (MCF7) were
subjected to a range of frequencies (50 kHz–2 MHz) similar to the previously tested SKOV3. For
the MCF7, an optimal frequency of 100 kHz was determined using the EIS, indicating a higher
sensitivity towards the applied field. Further experiments specifically targeting the two types of
cancer cells using HER2 antibody functionalized gold nanoparticles (HER2-AuNPs) were performed to determine if enhanced electric field strength can be induced via the application of
nanoparticles, consequently leading to the killing of the cancerous cells without affecting non
cancerous HUVECs and MCF10a providing a platform for the development of a non-invasive
cancer treatment without any harmful side effects. The EIS was used to monitor the real-time
consequences on cellular viability and a noticeable decrease in the growth profile of the MCF7 was
observed with the application of the HER2-AuNPs and the electric fields indicating specific inhibitory effects on dividing cells in culture. To further understand the effects of the externally
applied field to the cells, an Annexin V/EthD-III assay was performed to determine the cell death
mechanism indicating apoptosis. The zeta potential of the SKOV3 and the MCF7 before and after
incorporation of the HER2-AuNPs was also obtained indicating a decrease in zeta potential with
the incorporation of the nanoparticles. The outcome of this research will improve our fundamental understanding of the behavior of cancer cells and define optimal parameters of electrotherapy for clinical and drug delivery applications.
Key words: biosensor, electrotherapy, cancer, antibody, nanoparticles
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Introduction
The effects of exogenous electric fields on physiology and their possible relationship to diseases have
interested researchers for years [1-3]. In 1855, Guillaume Duchenne discovered that alternating current
leads to electrotherapeutic triggering of muscle contractions thus spurring the use of electrical energy as
medical treatment. Since then, the use of electric fields
has become popular in fields such as gene and cellular
therapies [4-6], and has even progressed to clinical
trials for drug delivery [7], however; still little is
known how electric fields may interact with intracellular signaling pathways to potentially alter cell
physiology.
The idea of classifying cancers by their electrical
properties was first proposed by Fricke and Morse in
1926 [8]. Recently, there has been interest in the use of
electrotherapy as a non-surgical and minimally invasive treatment for cancer, since the electrical and
physical properties of cancer cells differ from normal
proliferating cells. Electrical properties of cells determine most of the cellular functions, predominantly
proliferation and differentiation. In particular, the
transmembrane potential, the voltage difference
across the membrane produced by the balance of intracellular and extracellular ionic concentrations, is
responsible for controlling mitosis, DNA synthesis,
and the majority of other cell cycle phenomena [9].
Several studies have previously been done to derive
the relationship between transmembrane potential
and cell proliferation. Initially, Cone and Tongier
(1973) investigated the effects of transmembrane
modification on the mitotic activity of Chinese hamster ovary cells [10]. Their study showed that decreasing the cells transmembrane potential ultimately
stopped the mitotic process in the cells with the process being reversible once the transmembrane potential returned to a normal value. More recently, MCF-7,
human adenocarcinoma, membranes have been
shown to hyperpolarize during the G0/G1 phase of
proliferation [11]. Manipulation of these electrical
properties may provide a powerful electrotherapy
option for the treatment of cancer as cancerous cells
have been shown to have more electronegative
membrane potential than normal proliferating cells,
thus, further studies on cancer electrotherapy is warranted.
Current treatments for cancer have much potential; however, a major limitation in these treatments is
the negative side effects that occur. Electrotherapy for
cancer treatment is very promising alternative as it
eliminates the toxic chemicals and possible immunogenic responses in the host tissue. Current research for
cancer electrotherapy mostly focuses on using short
electric pulses to alter cell physiology, in particular,
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the permeabilization of the cell membrane. This phenomenon is then modified either by the addition of
chemotherapy agents [12], by inducing apoptosis of
the cells [13] or even for DNA vaccination against
certain cancer types [14-15]. However, there are limitations with this technique as it can only be efficient if
all tumor cells are permeabilized, and thus there is
also a size dependence of the tumor as smaller tumors
show a higher response rate to the therapy [16]. Also,
the electric field has to be as low as possible to ensure
the safety of the procedure to prevent unwanted side
effects such as erythema, edema, superficial epidermal erosion, or scars [12].
Previously, an electrical impedance sensor (EIS)
was used to explore the responses of cancerous
SKOV3 cells and normal HUVEC cells to low intensity
(<2 V/cm) AC electric fields, determining that the
optimal frequency for SKOV3 proliferation arrest was
200 kHz, without harming the non-cancerous HUVECs [17]. A slower proliferation rate was observed in
the cancer cells through the lower resistance curves of
the EIS in real-time as the external field was applied
compared to a control with no applied field (Scheme
1/Figure 8). In this study, we determined if the effects
of the externally applied electric field are cell type
dependant using human breast adenocarcinoma cells
(MCF7). The MCF7, along with non cancerous
MCF10a, were subjected to the range of frequencies
(50 kHz–2 MHz) similar to the previously tested
SKOV3 and HUVEC to determine the optimal frequency that would most hinder the proliferation of
the MCF7. Monitoring the behavior of different types
of cancerous cells under the effects of the electric field
can lead to specific treatment paradigms for various
types of cancers.
The ultimate fate of these cells after they endure
the effects of the applied field is the next focus of this
study. Nanomaterials are being considered in the development of new drugs and new therapies for disease control and improving the quality of life [18-20].
More recently, nanomaterials have been used in tissue
engineering and medical imaging, leading to improved diagnostics and new therapeutic treatments
[21-23]. Nanoparticles have been extensively studied
for use in biomedical applications, particularly gold
nanoparticles (AuNPs), due to their low cytotoxicity
[24], specifically for use in antibody targeted drug
delivery to cells [25]. For example, HER2, human epidermal growth factor receptor 2, is a cell membrane
surface-bound receptor tyrosine kinase that is responsible for intracellular signal transduction and
ultimately cell growth and differentiation [26]. HER2
over-expression leads to cancerous cell proliferation
and is seen in cancers such as breast cancer, ovarian
cancer, stomach cancer, and even lung cancer [27],
http://www.thno.org
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and both SKOV3 and MCF7 cells over-express HER2
markers on their surface membrane. It has also been
shown that in the presence of an electric field, AuNPs
could change the distribution of the field within the
cell’s cytoplasm resulting in an inward net electric
force which potentially could change the function of
the cell [28]. Thus, further experiments specifically
targeting the two types of cancer cells using HER2
antibody
functionalized
gold
nanoparticles
(HER2-AuNPs) were performed to determine if enhanced electric field strength can be induced via the
application of nanoparticles, consequently leading to
the killing of the cancerous cells without affecting non
cancerous HUVECs and MCF10a providing a platform for the development of a non-invasive cancer
treatment without any harmful side effects.
The EIS was used to monitor the real-time consequences on cellular viability under the electric field
with the incorporation of the HER2-AuNPs. The
binding of charged nanoparticles to the cell surface
plasma membrane will change the zeta potential value of the cells, a feature of the cell that has been used
in cell biology to study cell adhesion, activation, and
agglutination based on cell-surface-charge properties
[29]. Thus the zeta potential of the AuNPs,
HER2-AuNPs and each cell type before and after incorporation of the HER2-AuNPs was taken to monitor
this phenomenon. The HER2-AuNPs would bind to
the HER2 receptors on the membrane of the cancer
cells, thus affecting the cells’ zeta potential potentially
producing a larger effect of cell viability of the cancerous cells with the application of the electric field to
the combination of HER2-AuNPs and cell. The cell
death mechanism was also tested by using an Annexin V/EthD-III assay to determine if the cells undergo apoptosis or necrosis after the application of the
applied electric field.

Experimental Details
Cell culture
According to the American Cancer Society, every
year over 200,000 American women are diagnosed
with breast cancer, thus MCF7, human breast adenocarcinoma were chosen as another type of cancer cell
for comparison with the SKOV3. HTB-77™ (SKOV3)
and CRL-1730™ (HUVEC) cells were purchased from
American Type Culture Collection (ATCC, Rockville,
MD, USA) and were cultured in McCoy’s 5A Modified Medium and Dulbecco’s Modified Eagle Medium
respectively, each containing 10 % fetal bovine serum,
0.3 mg ml−1 L-glutamine, 100 U ml−1 penicillin and 100
mg ml−1 streptomycin. The HTB-22™ (MCF7) and
CRL-10317TM (MCF10a) were graciously donated
from the Research Institute at Miami Children's Hos-
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pital, Miami, FL, and were both cultured in Eagle's
Minimum Essential Medium containing 10 % fetal
bovine serum, 0.3 mg ml−1 L-glutamine, 100 U ml−1
penicillin and 100 mg ml−1 streptomycin. The cell
cultures were placed in an incubator (37 °C, 5 % CO2
atmosphere) for 24 hours prior to the experiment so
that the cells reached confluency with a final concentration of 105 cells ml−1. 0.4 ml of cell suspension was
inoculated into each well in the EIS chip for the experiments.

Electrical impedance sensing (EIS)
The EIS chip design was previously reported
[25]. In short, individual tissue culture wells of volume 9 × 9 × 10 mm3 are placed over an array of eight
detecting gold electrodes (250 μm in diameter) each
linked to a gold counter electrode (7 × 46 mm2).

Application of external electric field
The design of the application of the external
electric field to the EIS chip was previously described
[17]. In brief, a unique system of a pair of insulated
wires (BLK KYNAR 100’, conductor area 0.25 mm)
was designed to be placed in conjunction with the 8
well array design of the EIS chip. The wires were
placed in 4 of the wells with the other 4 wells used as
the control. The wires were placed 1mm apart to allow spacing to encompass the whole electrode area. A
Leader LFG-1300S Function Generator was used to
provide the square AC waves at the desired frequencies.

Synthesis of AuNPs
Hydrogen tetrachloroaurate (HAuCl4) (40 ml, 1.0
mM) was added to an Erlenmeyer flask (250 ml),
stirred and brought to the boil on a hotplate. Trisodium citrate (Na3C6H5O7) (4 ml, 1%) was added to the
boiling solution. Three minutes after the addition of
trisodium citrate, and 10 minutes of stirring, AuNPs
were formed. The size of the AuNPs was characterized by the Zetasizer (Malvern Instruments, Woodstock, GA) and TEM and found to be 20 nm, the size
indicated in the HER2 functionalization procedure.

HER2 antibody functionalization of AuNPs
The HER2 antibody preparation was done following the procedure of Zhu et al. [30]. In short, The
AuNPs solution was concentrated 5X and the pH of
the AuNPs solution for antibody labeling was adjusted to pH 8.5 ~ 9.0 with 0.2 ml of K2CO3 (0.1 M).
Purified Anti-ErbB2/Her2 Monoclonal Antibody (5
μl, 1 mg ml-1) was added to the AuNPs solution (750
μl, 5X) and stirred gently at room temperature for 1 h.
The conjugate was stabilized by adding BSA (90 μl,
10%) in sodium borate (20 mM) for a final concentration of 1% and the solution was incubated for another
http://www.thno.org
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15 min. The mixture was then centrifuged at 7000 rcf
for 15 min. Two phases can be obtained: a clear to
pink supernatant of unbound antibodies and a dark
red, loosely packed sediment of the AuNPs-Antibody
conjugates. The supernatant was discarded and the
pellet was resuspended in BSA/PBS (100 μl, 1%). After another centrifugation at 7000 rcf for 15 min, the
supernatant was removed and the pellet was resuspended in 100 μl buffer, containing sodium phosphate
(20 mM), Tween 20 (0.25%), sucrose (10%), and BSA
(5%). The conjugate was stored at 4° C until required
for use.

Apoptosis / Necrosis Assay
Apoptotic/Necrotic Cells Detection Kit was
purchased from PromoKine (Germany). The kit contains FITC-Annexin V in TE buffer containing 0.1%
BSA and 0.1% NaN3 (pH 7.5), EthidiumHomodimer
III (EthD-III) in PBS and 5X Binding Buffer. A 1:5 dilution of Binding Buffer to DI water was made. After
runs with the EIS, the cells were detached from the
wells on the chip with 0.25% Trypsin/EDTA and
suspended with the 1:5 Binding Buffer/DI solution
giving a final concentration of 105 cells ml−1. 100 μl of
the cell suspension was placed in a microcentrifuge
tube to which 5 μl of FITC-Annexin V and 5 μl of
EthidiumHomodimer III solutions were added to
each tube. The samples were incubated at room temperature for 15 minutes in the dark, after which the
cells were washed and resuspended with the 1:5
Binding Buffer/DI solution. Fluorescence intensity
was determined using a confocal microscope (Perkin
Elmer UltraViewVox system, USA) with FITC and
Texas Red filter sets.

Zeta potential measurement
The ZetasizerNano ZEN 3600 (Malvern Instruments, United Kingdom) was used to measure the
zeta potential of the AuNPs, HER2-AuNPs and the
HER2-AuNPs with each cell type, SKOV3, HUVEC,
MCF7 and MCF10a.

AFM imaging and analysis
AFM images of live cells were obtained in fluid
tapping mode using a Nanoscope IIIa multimode
system (Veeco Metrology, CA). The cells were grown
to confluency on Poly-L-Lysine coated glass coverslips. The AFM cantilever was positioned on four
different regions of the cell surface to acquire 5 µm × 5
µm topographical and amplitude images. Qualitative
analysis of the particles was performed by visualization of the amplitude and topographical images and
by quantitative analysis of roughness measurements
from the topographical images. Roughness values of
the cell surface were calculated from the topographical image in an offline mode using Nanoscope Image
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Analysis software (Version 5.13r1; Veeco Metrology).
Average cell membrane surface roughness measurements were obtained at various time points representing characteristics of the cell surface influenced by
NP attachment and internalization. A series of topographical images of SKOV3 cell surfaces were obtained when the cells were incubated in the medium
with and without AuNPs.

Results
Optimal frequency for MCF7
As done before with the SKOV3 cells, the MCF7
and MCF10 cells were subjected to five different frequencies of alternating electric fields 50, 100, 150 and
200 kHz and 2 MHz, to find the optimal frequency
that would most hinder the growth of the MCF7 cells
without harming the normal MCF10a cells. Figure 1
shows the EIS results of the MCF10a (1 (a), (c)) and the
MCF7 (1 (b), (d)) for the intermediate frequencies (100,
150, 200) and the extreme frequencies (50 kHz, 2 MHz)
respectively.
The breast cancer cell lines behaved in a similar
manner to the ovarian cancer cell lines tested previously as did the noncancerous MCF10a to the HUVECs. Under the influence of the electric field at all
five frequencies, the resistance values for the MCF10a
cells followed a trend of proliferating cells gradually
attaching and spreading across the electrode surface
creating an increase in resistance values. This can be
seen in Figures 1 (a) and (c) which show the resistance
values of the MCF10a when exposed to the intermediate range frequencies (100, 150, 200 kHz) and the
extreme frequencies (50 kHz, 2 MHz) respectively.
However, the MCF7 exhibited a variation of trends in
resistance profiles with the different frequencies of the
applied field. Shown in Figure 1 (b), 150 and 200 kHz
decreased the resistance profiles of the MCF7, however, the MCF7 have the lowest resistance profile with
100 kHz indicating the most affect on the cell proliferation at this frequency. The extreme frequencies
were also tested to justify that the intermediate frequencies are the target frequencies suitable for cancer
electrotherapy. The MCF10a cells retained a similar
profile with the applied field as without (Figure 1 (c)).
In Figure 1 (d), the MCF7 show more of a difference
when the extreme frequencies are applied compared
to the previously tested SKOV3. The higher frequency
of 2 MHz had an effect on the MCF7 proliferation as
can be seen in the lower resistance profile compared
to the control with no field applied. This could be due
to the more sensitive membrane of the MCF7 compared to that of the other types of cancer cells. Cancer
cells, in general, have lower membrane potentials
with lower stiffness compared to their normal counhttp://www.thno.org
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terparts. This is seen in the Young’s modulus of each
type of membrane using atomic force microscopy
(AFM) [31]. In addition, the MCF7 breast cancer cells
in general, were observed to have a lower Young’s
modulus in comparison with other types of cancer
cells, potentially giving the cells a weaker membrane.
50 kHz also slowed down the proliferation of the
MCF7 cells; however, the 100 kHz affected the proliferation of these cells the most.
Digital images of the cells were also taken for the
MCF10a and MCF7 cells with and without exposure
of the 100 kHz applied field. This was done to get a
visual understanding of the cell behavior on the EIS
electrode surface as the electric field is applied. The
changes in resistance profiles of the cells with and
without the applied field could be due to a slower
proliferation rate caused by the exposure to the field,
or simply, by the detachment of the cells from the
electrode. Figure 2 shows one well each of the
MCF10a cells after 20 hours without the applied field
(a), after 20 hours with the applied 100 kHz field (c),
the MCF7 cells after 20 hours without the applied
field (b), and after 20 hours with the applied 100 kHz
field (d). We see the MCF10a maintain a solid monolayer over the electrode after 20 hours of field expo-
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sure. However, for the MCF7, we do not see a solid
monolayer attached over the electrode. In the case of
cell detachment, there would be evidence of the detached cells floating in the surrounding media, thus
indicating the externally applied field having a detrimental affect towards the cell proliferation.

HER2-AuNPs targeted enhancement
Gold nanoparticles are being use in targeted
therapies in biomedical engineering such as gene and
drug delivery transfection vectors, DNA-binding
agents and in various imaging systems due to their
inert properties [32]. In this study, we functionalized
our AuNPs with a HER2 antibody for a targeted delivery of the particles to the cell membrane since
HER2 is overexpressed in both breast and ovarian
cancers, and based on the length of the experiment,
the AuNPs were assumed to remain on the membrane
surface during this experiment. We tested the two
types of cancer cells, SKOV3 and MCF7, as well as the
non cancerous HUVECs and MCF10a, under their
respective optimal frequencies, 200 and 100 kHz, with
and without the integration if the HER2-AuNPs to
determine any enhancement in the effects of the applied electric field.

Figure 1. Resistance values of MCF10a (a) and MCF7 (b) under electric fields of frequencies 100, 150 and 200 kHz. No apparent effect was noticed for the normal
MCF10a, however, a significant decrease in resistance values was observed for the MCF7 for all three frequencies. 50 kHz and 2 MHz frequencies were tested on both
MCF10a (c) and MCF7 (d). The MCF10a showed no apparent effect on the cell proliferation as seen in the similar resistance curves to the control. 100 kHz showed
the largest decrease out of all the frequencies for the MCF7.

http://www.thno.org
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Figure 2. MCF 10a cells after 20 hours without the applied field (a), after 20 hours with the applied 100 kHz field (c), the MCF 7 cells after 20 hours without the
applied field (b), and after 20 hours with the applied 100 kHz field (d). We see the MCF 10a maintain a solid monolayer over the electrode after 20 hrs of field
exposure. However, for the MCF 7, we do not see a solid monolayer attached over the electrode indicating a decrease in cell proliferation. In the case of cell
detachment, there would be evidence of the detached cells floating in the surrounding media.

The first concern with using the metallic nanoparticles under the applied electric field would be the
potential heating of the nanoparticles. AuNPs are being used for cancer hyperthermia studies [33], however, these studies use nearinfrared (NIR) laser light,
[34] radiowaves, [35] or even ultrasound [36]. To
make sure temperature would not be a factor for the
cancer cells under the intermediate frequencies determined for the two types of cancer cells, we tested
the temperature of the wells at incremental times of 6
hours for the SKOV3 and 4 hours for the MCF7 for an
entire run. Figure 3 (a) and (b) shows the average
temperature of the 8 wells on one chip for the SKOV3
and the MCF7, respectively. Here we do not see any
significant change in the tested temperatures when
the HER2-AuNPs were incorporated for either type of
cell, indicating no apparent thermal effects from the
nanoparticles. Figure 4 (a) and (c) shows the resistance
values obtained for the noncancerous HUVECs and
MCF10a, respectively. As in the previous experiment,
there is no noticeable change in the resistance values
when the electric field was applied to the cells compared to the control cells with now applied field. Also,
with the incorporation of the HER2-AuNPs, there is
still no apparent effect in the resistance profiles.
However, a noticeable decrease in the growth profiles

of the SKOV3 and MCF7 was observed with the application of the HER2-AuNPs and the electric fields
compared to just the field itself indicating specific
inhibitory effects on dividing cells in culture (Figure 4
(b) and (d)).
Gold nanoparticles with sizes ranging from a
few nanometers up to one hundred nanometers are
most commonly used for study cell-nanoparticle interactions. To achieve effective targeting, the HER2
antibody functionalized AuNPs with a series of sizes
are tested. Transmission electron microscopy (TEM)
analysis, AFM, and the Zetasizer (Malvern Instruments, Woodstock, GA) were performed for the determination of particle sizes. Over 100 particles were
counted in multiple pictures from different areas of
the TEM grid resulting a size variation of ±10%. The
detail of nanoparticle preparation and characterization can be found in our previous publication (17,
46-48). We found that the antibody functionalized
AuNPs in the size range from 10 to 30 nm covered cell
surface more uniformly and efficiently than the particles outside this range. Instead of casting cell surface,
particles with size bigger than 30 nm are found to be
more easily entering cells via endocytosis process
leading to less effect on cells upon electrical field
stimulation.
http://www.thno.org
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Figure 3. Average temperature readings for the 8 wells on a chip at various time points throughout an EIS run for SKOV3 (a) and MCF7 (b).

Figure 4. Resistance values for HUVECs (a), SKOV3 (b), MCF10a (c) and MCF7 (d) under the effects of the optimal frequencies (SKOV3 200 kHz, MCF7 100 kHz)
with and without the application of HER2-AuNPs.

AFM characterization in wet condition was
conducted to observe the nanoparticle-cell interaction
by quantitative analysis of the roughness of cell
membrane upon nanoparticle exposure. Time-lapsed
(1, 3 and 24 hours) AFM amplitude images were performed on the cells treated with and without HER2

antibody modified AuNPs. From the amplitude images it is clear that the cells treated with HER2 antibody showed higher number of AuNPs attached on
the cell surface when compared to the
non-functionalized AuNPs. Compared to the roughness of cell membrane exposed to the normal AuNPs
http://www.thno.org
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(Figure 5b), the higher roughness (Figure 5a) of upon
exposure by antibody modified AuNPs indicating the
specific binding of functionalized nanoparticles to the
cell surface. The HER2 antibody functionalized particles clearly specifically bind to the HER2 receptors on
the membrane of cancer cells.
Amplitude images obtained at 24 hours (Figure
5c) showed that upon HER2-AuNPs exposure, there
was a significant number of particles present on the
cell surface, indicating that the antibody functionalized AuNPs remained on the cell membrane surface
during this experiment.

Apoptosis / Necrosis Assay
Apoptosis and necrosis are the two major processes leading to cell death. Apoptosis is the process
of programmed cell death caused by a cascade of biochemical signals within the cell and can be triggered
from a variety of external factors usually in the form
of stress towards the cell. In the case of apoptosis, the
cell prepares itself by performing changes within, one
of them being changes in the phospholipid content of
the cell membrane.
Apoptotic cells can be easily identified with the
protein Annexin V, which is binds to phosphatidylserine, a protein located in the cell membrane. Under
normal circumstances, the phosphatidylserine is
found in the inner layer of the cell membrane double
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layer. In the early stages of apoptosis, these phosphatidylserine proteins move to the outer layer of the
membrane where Annexin V labeled with fluorescein
(FITC) can bind, staining apoptotic cells green.
Necrosis is a traumatic cell death that results
from any acute damage caused to the cell where the
cell membrane integrity is compromised. This results
in the cytosol and organelles within the cell to spill
into the surrounding environment. Ethidiumhomodimer III (EthD-III) is a highly positively charged
nucleic acid probe which binds to DNA, thus is used
to classify necrotic cells by staining them with red
fluorescence.
To further understand the effects of the externally applied field to the cells, an Annexin V/
EthD-III assay was performed to determine the cell
death mechanism with green fluorescent membrane
staining indicating apoptotic cells, and red fluorescent
nuclear staining necrotic cells. Figure 6 shows the
fluorescent staining of MCF7 cells from one well after
20 hours of exposure to 100 kHz electric field. The
image on the left shows EthD-III stained cells (necrotic) and the image on the right shows Annexin V
stained cells (apoptotic). There are significantly more
cells stained with the Annexin V indicating the death
mechanism triggered from the applied electric field to
be apoptosis.

Figure 5. AFM amplitude images showing the surface topography of SKOV-3 cell membrane after treating with and without HER2 modified –AuNPs for 3 hours. It
is to be noted that the cells treated with HER2 modified –AuNPs (a) showed more number of particles on the cell surface than the cells treated non modified NPs
(b). Figure 5C showing the surface topography of SKOV-3 cell membrane after treating with HER2 modified –AuNPs for 24 hours.

Figure 6. Fluorescent staining of MCF7 cells after 20 hours of exposure to 100 kHz electric field. The image on the left shows EthD-III stained cells (necrotic) and
the image on the right shows Annexin V stained cells (apoptotic).

http://www.thno.org
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Zeta Potential Measurements
Due to electrostatic forces, the interior of the cell
has uniform potential and a voltage drop across the
plasma membrane. With the application of any external electric field, the first electrostatic force encountered would be the membrane potential. Cancerous cells have been shown to have lower cell and
cytoplasmic conductivity as well as a lower membrane capacitance compared to non-cancerous cells
[37]. This outermost electrically negative zone is
composed of negatively charged sialic acid molecules
found on the tops of glycoproteins extending outward
from the cell membrane. The zeta potential, the potential that exists at the electrical double layer of a
particle or cell, is created from these sialic acid residues. Cancer cells have significantly more sialic acid
molecules and thus a greater surface negativity. Thus,
any external factor that would affect these residues
would change the surface negativity of the cell.
In 1990, Seeger and Wolz correlated the electronegativity of cancer cell membranes with membrane
degeneration throughout the process of carcinogenesis [38]. This process involves the degradation of the
external cell membrane initially, causing more permeability to water-soluble substances to potassium,
magnesium, and calcium migrate from the cells and
sodium and water accumulate in the cell interior. This
is then followed by degenerative changes in the inner
membrane of the mitochondria causing loss of anchorage of critical mitochondrial enzymes. Since the
membrane potential in a cancer cell is lower than the
membrane potential of a healthy cell, the electrical
field across the membrane of a cancer cell is reduced.
The reduction in membrane electrical field strength
will in turn cause alterations in the metabolic functions of the cell.
In order to understand the effects of the applied
electric field with targeted nanoparticle enhancement,
the next focus of the study was to observe the zeta
potential of the cells before and after exposure to the
nanoparticles. Zeta potential is the electrostatic potential near the surface of a particle and usually this
surface charge is counterbalanced by charges of opposite sign in the surrounding solution. With the nanoparticles, once in contact with the cell membrane,
the surface charges of the particles may affect the cells
membrane properties with negatively charged ions or
molecules will decrease and positively charged ions
will increase the surface zeta potential of the cell
[39-40], thus attachment of negatively charged nanoparticles on the cell’s membrane will cause its zeta
potential to become more negative.
We measured the zeta potential of our AuNPs
before and after functionalization with the HER2 an-
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tibody to see if the antibody would affect the nanoparticles’ zeta potential. We then measured the zeta
potential of the two cancer cell lines, SKOV3 and
MCF7, with and without the incorporation of the
HER2-AuNPs and compared the results to those for
the non cancerous cell lines, HUVEC and MCF10a,
respectively (Figure 7). In all cases, the bare AuNPs
had the lowest zeta potentials with values of -37.4 ±
0.7, -40.0 ± 0.05, -43.3 ± 0.7, and -39.3 ± 0.4 as shown in
Figure 7 (a), (b), (c) and (d), respectively. With the
functionalization of the HER2 antibody, the zeta potentials increased slightly for each case (-30.5 ± 1.4,
-37.1 ± 1.2, -41.6 ± 1.0, -35.5 ± 0.6). The cells themselves
had initial zeta potentials of -19.2 ± 0.9 (HUVEC), -19.3
± 0.8 (SKOV3), - 20.5 ± 0.9 (MCF10a) and -28.3 ± 1.3
(MCF7). After incubation with the HER2-AuNPs, the
cancerous cell showed a significant decrease in zeta
potentials compared to the non-cancerous cells. For
the HUVECs, the zeta potential slightly increased to
-18.3 ± 0.9, and the MCF10a also showed a slight increase to -18.9 ± 2.3.(Figure 7 (a), (c), respectively). The
case was different for both cancerous cell types as the
zeta potentials dropped after HER2-AuNPs functionaliztion for the SKOV3 to -25.3 ± 1.3, and for the MCF7
to -37.6 ± 1.3 (Figure 6 (b), (d), respectively).

Discussion
The cell membrane provides a barrier for the cell
and its surroundings and as a result is the first line of
defense for the cell to survive. The membrane controls
the exchange of electrically charged ions across the
cell membrane thus creating the cell membrane potential. It is this potential that is the underlying characteristic of the cell that could distinguish between
normal and cancerous cells. It was been noted before
that cancerous cell have a lower membrane potential,
and it has been shown that the cell’s membrane
changes during cancer transformation, in particular
the membrane’s fluidity and charge [41-42]. Therefore, by altering the cell membrane potential, one
could possibly control the fate of the cell.
Cancerous cell membranes have a higher number of negatively charged sialic acids, which regulate
intercellular contacts and the interaction of charged
macromolecules with the cell surface [43]. It is the
number of sialic acids that lead to any cell’s overall
negative membrane potential and ultimately determines a cell’s zeta potential [44]. Sialyation is one of
the factors that cause the cancer cell membrane to be
more electronegative and consequently, any factor
that increases or decreases the number of sialic acid
residues will change the degree of membrane negativity.
We had proposed that gold nanoparticles functionalized with specific antibodies to target the cancer
http://www.thno.org
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cells would enhance the effects of the electric field
towards the cells without affecting the non-cancerous
cells due to the different membrane properties of the
cancerous cells. In our study, the antibody used targeted HER2 glycoprotein receptor on the cell membrane. Since sialic acids are generally found at the end
of most glycoproteins, and the specific cancer cells
tested overexpress the HER2 receptor, we can deduce
that there would be more HER2-AuNPs attracted to
the cancer cells as opposed to the regular cells (Figure
8).
With more negatively charged HER2-AuNPs
attached to the cancer cell membrane, the cell membrane could more vulnerable to the affects of the external electric field due to the decrease in surface
charge. An important consequence of the existence of
electrical charges on the surface of particles is that
they will exhibit certain effects under the influence of
an applied electric field. Since the changes in zeta potential values depend on cell surface charge, nanoparticle surface charge and their interaction we observed a decrease in zeta potentials of the cells after
nanoparticle incorporation leaving the cells more
vulnerable to the detrimental effects of the applied
electric field.
There was also a noticeable difference in the behavior between the two types of cancer cells. The
breast cancer cell line, MCF7 was affected by a lower
frequency than the ovarian cancer cell line, SKOV3.
This could be due to the MCF7 having a more simpli-
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fied cytoskeleton compared with MCF10A, which
results in less stiffness and easier deformation [45].

Conclusion
Cancer electrotherapy treatments are showing
considerable promise to avoid the negative side effects of traditional cancer treatments such as chemotherapy. We previously demonstrated that cancer cell
proliferation is affected by externally applied alternating electric fields in the intermediate frequency
range of 100 kHz – 200 kHz. In this study, we
demonstrated that different types of cancer cells are
affected by different optimal frequencies of these
electric fields. To further understand the effects of the
applied fields on the cells, we performed an Annexin
V/ EthD-III assay to conclude the fate of the cells as
apoptosis. We also observed a decrease in proliferation with the addition of HER2-AuNPs to target the
cancer cells and enhance the effects of the electric field
towards the cells without affecting the non-cancerous
cells. With the attached nanoparticles, the zeta potential of the SKOV3 and the MCF7 before and after incorporation of the HER2-AuNPs decreased compared
to their non-cancerous counterparts. The decrease in
membrane potential would thus leave the cells more
vulnerable to the detrimental effects of the applied
electric field. The outcome of this research will improve our fundamental understanding of the behavior
of cancer cells and define optimal parameters of electrotherapy for clinical and drug delivery applications.

Figure 7. Zeta potential values for HUVECs (a), SKOV3 (b), MCF10a (c), and MCF7 (d). With the integration of the HER2-AuNPs, the zeta potential of both cancer
cells decreased in comparison to the two noncancerous cell types.
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Figure 8. Schematic representation of the cells with and without HER2-AuNPs coating in the field of electrical stimulation.
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